Table 1.
The baseline characteristics of patients included in this study.
| Characteristics | TCGA (n, %) | ICGC (n, %) |
|---|---|---|
| Age | ||
| > 65 | 69 (49.3%) | 35 (55.6%) |
| ≤ 65 | 71 (50.7%) | 28 (44.4%) |
| Gender | ||
| Female | 66 (47.1%) | 32 (50.8%) |
| Male | 74 (52.9%) | 31 (49.2%) |
| Smoking | ||
| Yes | 63 (45.0%) | – |
| No | 50 (35.7%) | – |
| NA | 27 (19.3%) | – |
| Alcohol | ||
| Yes | 79 (56.4%) | – |
| No | 49 (35.0%) | – |
| NA | 12 (8.57%) | – |
| Diabetes | ||
| Yes | 31 (22.1%) | – |
| No | 85 (60.7%) | – |
| NA | 24 (17.1%) | – |
| Chronic pancreatitis | ||
| Yes | 11 (7.86%) | – |
| No | 100 (71.4%) | – |
| NA | 29 (20.7%) | – |
| Grade | ||
| G1 | 18 (12.9%) | 1 (1.59%) |
| G2 | 81 (57.9%) | 39 (61.9%) |
| G3-4 | 41 (29.3%) | 22 (34.9%) |
| GX | – | 1 (1.59%) |
| Tumor location | ||
| Head of Pancreas | 114 (81.4%) | – |
| Body & Tail of Pancreas | 20 (14.3%) | – |
| Other | 6 (4.29%) | – |
| Tumorsize | ||
| ≤ 2 cm | 5 (3.57%) | – |
| > 2 cm & ≤ 4 cm | 84 (60.0%) | – |
| > 4 cm | 51 (36.4%) | – |
| Stage | ||
| I | 11 (7.86%) | – |
| II | 123 (87.9%) | – |
| III/IV | 6 (4.29%) | – |
| T stage | ||
| T1 | 4 (2.86%) | – |
| T2 | 14 (10.0%) | 4 (6.35%) |
| T3 | 119 (85.0%) | 56 (88.9%) |
| T4 | 3 (2.14%) | 1 (1.59%) |
| TX | – | 2 (3.17%) |
| N stage | ||
| N0 | 35 (25.0%) | 16 (25.4%) |
| N1 | 105 (75.0%) | 45 (71.4%) |
| Nx | – | 2 (3.17%) |
| M stage | ||
| M0 | 67 (47.9%) | 2 (3.17%) |
| M1 | 3 (2.14%) | 3 (4.76%) |
| Mx | 70 (50.0%) | 58 (92.1%) |
| Survival status | ||
| Alive | 57 (40.7%) | 26 (41.3%) |
| Dead | 83 (59.3%) | 37 (58.7%) |
| KRAS mutation | ||
| Yes | 66 (47.1%) | – |
| No | 53 (37.9%) | – |
| NA | 21 (15.0%) | – |
| TP53 mutation | ||
| Yes | 69 (49.3%) | – |
| No | 50 (35.7%) | – |
| NA | 21 (15.0%) | – |